TCMC

Soleo Health Prepared to Meet Increased Demand of FDA-Approved LEQEMBI™ (lecanemab-irmb) to Treat Alzheimer’s Disease

Retrieved on: 
Thursday, July 6, 2023

In January 2023, Soleo Health was selected by Eisai Inc., a developer of pharmaceuticals, as the specialty pharmacy distribution partner for LEQEMBI to treat Alzheimer’s Disease. At that time, the highly anticipated treatment -- an anti-amyloid monoclonal antibody used to treat mild cognitive impairment (MCI) due to Alzheimer’s Disease and mild Alzheimer’s Disease (collectively known as early Alzheimer’s Disease) -- had received fast-track FDA approval initially. Today, LEQEMBI received full FDA approval.

Key Points: 
  • In January 2023, Soleo Health was selected by Eisai Inc., a developer of pharmaceuticals, as the specialty pharmacy distribution partner for LEQEMBI to treat Alzheimer’s Disease.
  • At that time, the highly anticipated treatment -- an anti-amyloid monoclonal antibody used to treat mild cognitive impairment (MCI) due to Alzheimer’s Disease and mild Alzheimer’s Disease (collectively known as early Alzheimer’s Disease) -- had received fast-track FDA approval initially.
  • Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the Company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
  • For more information about LEQEMBI therapy and services through Soleo Health, contact the Company’s Alzheimer’s Disease TCMC at 844.960.9090 or email [email protected] .

Soleo Health Selected as Sole Specialty Pharmacy Distributor of Newly FDA-Approved LEQEMBI™ (lecanemab-irmb) for Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, January 10, 2023

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD).

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD).
  • Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the Company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
  • “The selection of Soleo Health as the sole specialty pharmacy distributor for LEQEMBI reflects confidence in our clinical expertise and differentiated patient care model supporting patients in the neurology space.
  • For more information about LEQEMBI therapy and services through Soleo Health, contact the Company’s Alzheimer’s Disease TCMC at 844.960.9090 or via email at [email protected] .

Soleo Health Named a Limited Drug Distribution Partner by Mitsubishi Tanabe Pharma America for RADICAVA ORS®

Retrieved on: 
Tuesday, June 7, 2022

Each new ALS patient under Soleo Healths care is assigned a Soleo Health patient ambassador who can help address any questions.

Key Points: 
  • Each new ALS patient under Soleo Healths care is assigned a Soleo Health patient ambassador who can help address any questions.
  • Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc (MTPA).
  • Do not receive RADICAVA ORS (edaravone) if you are allergic to edaravone or any of the ingredients in RADICAVA ORS.
  • For more information, including full Prescribing Information and Patient Information, please visit WWW.RADICAVAORS.COM
    RADICAVA and RADICAVA ORS are registered trademarks of Mitsubishi Tanabe Pharma America, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005419/en/

Soleo Health Selected as Limited Distribution Partner for VYVGART™

Retrieved on: 
Monday, January 24, 2022

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it was selected as a limited distribution partner for VYVGART (efgartigimod alfa-fcab) by argenx SE .

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it was selected as a limited distribution partner for VYVGART (efgartigimod alfa-fcab) by argenx SE .
  • Effective immediately, Soleo Health is able to manage and administer VYVGART intravenously in patients homes or its ambulatory infusion centers nationwide.
  • Soleo Health is at the forefront of bringing revolutionary specialty pharmaceuticals to patients nationwide with this new partnership with argenx.
  • Our ever-growing limited drug distribution portfolio continues to expand as we are increasingly recognized for our capabilities, particularly within the autoimmune and neurology arenas, said Drew Walk, Soleo Health chief executive officer.

Soleo Health Unveils Therapeutic Care Management Center Dedicated to Thyroid Eye Disease Patients

Retrieved on: 
Monday, September 13, 2021

Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the unveiling of its Thyroid Eye Disease (TED) Therapeutic Care Management Center (TCMC), dedicated to caring for and treating patients with thyroid eye disease , a rare ophthalmic, vision-threatening condition.

Key Points: 
  • Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the unveiling of its Thyroid Eye Disease (TED) Therapeutic Care Management Center (TCMC), dedicated to caring for and treating patients with thyroid eye disease , a rare ophthalmic, vision-threatening condition.
  • Soleo Health patients receiving care through the TED TCMC are treated with TEPEZZA , the first and only U.S. Food and Drug Administration-approved treatment for TED.
  • Thyroid eye disease affects an estimated 16 per 100,000 women and 2.9 per 100,000 men in the general population.
  • Soleo Health is pleased to add TEPEZZA to our growing portfolio of specialty pharmaceutical treatments, stated Drew Walk, Soleo Healths chief executive officer.